Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 Group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and envelope protein boost

Journal of Virology

Volumn 89, Issue 12, 2015, Pages 6462-6480

  Hulot, Sandrine L ^a   Korber, Bette ^b   Giorgi, Elena E ^b   Vandergrift, Nathan ^c   Saunders, Kevin O ^c   Balachandran, Harikrishnan ^a   Mach, Linh V ^a   Lifton, Michelle A ^a   Pantaleo, Giuseppe ^d   Tartaglia, Jim ^e   Phogat, Sanjay ^e   Jacobs, Bertram ^f   Kibler, Karen ^f   Perdiguero, Beatriz ^g   Gomez, Carmen E ^g   Esteban, Mariano ^g   Rosati, Margherita ^h   Felber, Barbara K ^h   Pavlakis, George N ^h   Parks, Robert ^c   Lloyd, Krissey ^c   Sutherland, Laura ^c   Scearce, Richard ^c   Letvin, Norman L ^a   Seaman, Michael S ^a   Alam, S Munir ^c   Montefiori, David ^c   Liao, Hua Xin ^c   Haynes, Barton F ^c   Santra, Sampa ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e Sanofi Pasteur   (Canada)

^f Arizona State University   (United States)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BINDING ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLOBAL TRIVALENT MOSAIC ENV PROTEIN; GROUP M CONSENSUS ENV; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PRIMER DNA; RECOMBINANT NYVAC VECTOR; TRANSMITTED FOUNDER B CLADE ENV B 1059; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE; VIRUS VECTOR; ASPARTATE AMINOTRANSFERASE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SUBUNIT VACCINE; VIRUS ANTIGEN;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ANTIGENICITY; DRUG CROSS REACTIVITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RHESUS MONKEY; SEQUENCE ANALYSIS; SURFACE PLASMON RESONANCE; UPREGULATION; VACCINATION; VACCINE PRODUCTION; ANIMAL; BLOOD; COMPARATIVE STUDY; CONSENSUS SEQUENCE; GENETICS; HUMAN; IMMUNOLOGY; PROCEDURES; SECRETION (PROCESS);

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; ASPARTATE AMINOTRANSFERASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CONSENSUS SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; HIV ANTIBODIES; HIV-1; HUMANS; INTERFERON-GAMMA; MACACA MULATTA; SAIDS VACCINES; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84929589946     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00383-15     Document Type: Article

References (50)

1. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360. http://dx.doi.org/10.1126/science.1070441.
2. Letvin NL. 2006. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6:930-939. http://dx.doi.org/10.1038/nri1959.
3. Letvin NL. 2002. Strategies for an HIV vaccine. J Clin Invest 110:15-20. http://dx.doi.org/10.1172/JCI15985.
4. Nabel GJ. 2001. Challenges and opportunities for development of an AIDS vaccine. Nature 410:1002-1007. http://dx.doi.org/10.1038/35073500.
5. Walker BD, Ahmed R, Plotkin S. 2011. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med 17:1194-1195. http://dx.doi.org/10.1038/nm.2529.
6. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL. 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155:531-539. http://dx.doi.org/10.1016/j.cell.2013.09.061.
7. Heeney JL. 2004. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 3:S53-S64. http://dx.doi.org/10.1586/14760584.3.4.S53.
8. McMichael A. 2006. HIV vaccines. J Annu Rev Immunol 24:227-255. http://dx.doi.org/10.1146/annurev.immunol.24.021605.090605.
9. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. 2014. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-508. http://dx.doi.org/10.1038/nature12893.
10. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527. http://dx.doi.org/10.1038/nature10003.
11. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT. 2007. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13:100-106. http://dx.doi.org/10.1038/nm1461.
12. Korber B, Gnanakaran S. 2009. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 4:408-417. http://dx.doi.org/10.1097/COH.0b013e32832f129e.
13. Korber BT, Letvin NL, Haynes BF. 2009. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 83:8300-8314. http://dx.doi.org/10.1128/JVI.00114-09.
14. De Rosa SD, McElrath MJ. 2008. T cell responses generated by HIV vaccines in clinical trials. Curr Opin HIV AIDS 3:375-379. http://dx.doi.org/10.1097/COH.0b013e3282fbaaa7.
15. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893. http://dx.doi.org/10.1016/S0140-6736(08)61591-3.
16. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91. http://dx.doi.org/10.1038/nature07469.
17. Barouch DH, Korber B. 2010. HIV-1 vaccine development after STEP. Annu Rev Med 61:153-167. http://dx.doi.org/10.1146/annurev.med.042508.093728.
18. Corey L, McElrath MJ. 2010. HIV vaccines: mosaic approach to virus diversity. Nat Med 16:268-270. http://dx.doi.org/10.1038/nm0310-268.
19. Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF. 2004. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 3:S161-S168. http://dx.doi.org/10.1586/14760584.3.4.S161.
20. McBurney SP, Ross TM. 2007. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des 13:1957-1964. http://dx.doi.org/10.2174/138161207781039841.
21. Mullins JI, Nickle DC, Heath L, Rodrigo AG, Learn GH. 2004. Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines 3:S151-S159. http://dx.doi.org/10.1586/14760584.3.4.S151.
22. Thurmond J, Yoon H, Kuiken C, Yusim K, Perkins S, Theiler J, Bhattacharya T, Korber B, Fischer W. 2008. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24:1639-1640. http://dx.doi.org/10.1093/bioinformatics/btn251.
23. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, Ma BJ, Muldoon M, Theiler J, Nabel GJ, Letvin NL, Korber BT, Hahn BH, Haynes BF, Gao F. 2006. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 groupmconsensus env immunogen. J Virol 80:6745-6756. http://dx.doi.org/10.1128/JVI.02484-05.
24. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F, Haynes BF, Shaw GM, Korber BT, Hahn BH. 2006. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352:438-449. http://dx.doi.org/10.1016/j.virol.2006.05.011.
25. Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia SM, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B. 2013. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87:4185-4201. http://dx.doi.org/10.1128/JVI.02297-12.
26. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-323. http://dx.doi.org/10.1038/nm.2089.
27. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, Theiler J, Szinger J, Balachandran H, Buzby A, Quinn D, Parks RJ, Tsao CY, Carville A, Mansfield KG, Pavlakis GN, Felber BK, Haynes BF, Korber BT, Letvin NL. 2010. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 16:324-328. http://dx.doi.org/10.1038/nm.2108.
28. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJ, Ndung'u T, Barouch DH, Walker BD. 2011. Mosaic HIV-1 Gag antigens can be processed and presented to human HIVspecific CD8+ T cells. J Immunol 186:6914-6924. http://dx.doi.org/10.4049/jimmunol.1004231.
29. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, Carlson KR, Mach L, Kong WP, McKee K, Yang ZY, Rao SS, Mascola JR, Nabel GJ, Korber BT, Letvin NL. 2012. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428:121-127. http://dx.doi.org/10.1016/j.virol.2012.03.012.
30. Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, Pandrea I, Shaw GM, Hahn BH, Letvin NL, Nabel GJ, Korber BT. 2012. Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol 86:13217-13231. http://dx.doi.org/10.1128/JVI.01862-12.
31. Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. 2012. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically infected, ART-treated HIV patients. Eur J Immunol 42:3038-3048. http://dx.doi.org/10.1002/eji.201242696.
32. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105:7552-7557. http://dx.doi.org/10.1073/pnas.0802203105.
33. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5:e1000414. http://dx.doi.org/10.1371/journal.ppat.1000414.
34. Rose PP, Korber BT. 2000. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 16:400-401. http://dx.doi.org/10.1093/bioinformatics/16.4.400.
35. Gomez CE, Perdiguero B, Cepeda MV, Mingorance L, Garcia-Arriaza J, Vandermeeren A, Sorzano CO, Esteban M. 2013. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome. J Virol 87:7282-7300. http://dx.doi.org/10.1128/JVI.03246-12.
36. Kuroda MJ, Schmitz JE, Barouch DH, Craiu A, Allen TM, Sette A, Watkins DI, Forman MA, Letvin NL. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 187:1373-1381. http://dx.doi.org/10.1084/jem.187.9.1373.
37. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui HH, Grey H, Sette A. 2006. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24:817-819. http://dx.doi.org/10.1038/nbt1215.
38. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, Hahn BH, Haynes BF, Letvin NL. 2008. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 105:10489-10494. http://dx.doi.org/10.1073/pnas.0803352105.
39. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131-146. http://dx.doi.org/10.1016/j.jim.2013.11.022.
40. Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC. 2014. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol 88:12623-12643. http://dx.doi.org/10.1128/JVI.01705-14.
41. Giorgi EE, Balachandran H, Muldoon M, Letvin NL, Haynes BF, Korber BT, Santra S. 2014. Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine 32:3995-4000. http://dx.doi.org/10.1016/j.vaccine.2014.04.040.
42. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 110:6626-6633. http://dx.doi.org/10.1073/pnas.1304288110.
43. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, Karp M, Benjamini Y, Hochberg Y, Laron Z. 1995. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 45:486-490. http://dx.doi.org/10.1016/0306-9877(95)90228-7.
44. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77. http://dx.doi.org/10.1084/jem.20071331.
45. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
46. Sarzotti-Kelsoe M, Daniell X, Todd CA, Bilska M, Martelli A, LaBranche C, Perez LG, Ochsenbauer C, Kappes JC, Rountree W, Denny TN, Montefiori DC. 2014. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods 409:147-160. http://dx.doi.org/10.1016/j.jim.2014.02.013.
47. Haynes BF, Verkoczy L. 2014. AIDS/HIV. Host controls of HIV neutralizing antibodies. Science 344:588-589. http://dx.doi.org/10.1126/science.1254990.
48. Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Jr, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR, Lehmann C, Fatkenheuer G, Williams C, Shingai M, Martin MA, Bjorkman PJ, Seaman MS, Zolla-Pazner S, Karlsson Hedestam GB, Nussenzweig MC. 2014. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med 211:2361-2372. http://dx.doi.org/10.1084/jem.20141050.
49. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
50. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79:10103-10107. http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005.